Please login to the form below

Not currently logged in
Email:
Password:

Purdue looks to Merck for new CEO

Mark Timney will lead pain specialist
Mark Timney, Purdue Pharma

Purdue Pharma has appointed Merck & Co veteran Mark Timney as CEO, replacing John Stewart who retires.

Timney spent 15 years at Merck, where he most recently served as president of global primary care.

His previous roles include president of Merck US, during which time he helped to launch the hepatitis C drug Victrelis (boceprevir) and led the acquisition of ophthalmology company Inspire Pharmaceuticals.

Prior to moving to the US, Timney served as Merck's country manager in Korea and then Japan following a period in Australia.

Before joining Merck, he spent eight years in sales and marketing at a number of pharmaceutical companies, including Zeneca in New Zealand, ICI Pharmaceuticals in Australia, and Roussel Labs in the United Kingdom

Dr Raymond Sackler, co-founder and board member of pain specialist Purdue, said they had found a “proven leader” in Timney.

"I am confident that his capabilities and experience, coupled with Purdue's culture of excellence, will grow our business and strengthen our healthcare industry leadership,” said Sackler.

30th January 2014

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

Pharma index map
The 2019 CPhI Pharma Index Report
Examining this year’s industry performance...
Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...

Infographics